Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1985-7-11
|
pubmed:abstractText |
A phase I-II study of human recombinant interferon gamma (rIFN-gamma) was conducted in patients with various advanced cancer refractory to standard chemotherapies. In the phase I study, seven patients received 14 courses of escalating doses ranging from 2 X 10(6)U/m2 to 64 X 10(6)U/m2 by 1-hour intravenous infusion for 5 consecutive days. The toxicities were high fever with chills, anorexia, occasional nausea and vomiting, elevation of serum GOT, and dose-related leukopenia and neurotoxic symptoms such as heavy fatigue with somnolence or lethargy, both of which were reversible. The pharmacokinetics showed that the peak levels of serum rIFN-gamma activity were dose-related but decreased rapidly to below measurable levels within 6 hours after infusion in patients receiving less than 12 X 10(6)U/m2. Considering these data, the dosage of rIFN-gamma 6 X 10(6) U/m2 by daily intramuscular injection for more than 4 weeks was selected for the early phase II study. There was no partial response out of 11 evaluable patients but a stable condition was observed in 2 cases of renal cell carcinoma and one case each of breast cancer and ovarian cancer. All toxicities seen were similar to those observed in the phase I study, but no tachyphylaxis developed with continued dosage. The antitumor effect of rIFN-gamma remains to be evaluated in a further study employing higher doses.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0385-0684
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1331-8
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:2988459-Adult,
pubmed-meshheading:2988459-Aged,
pubmed-meshheading:2988459-Breast Neoplasms,
pubmed-meshheading:2988459-Carcinoma, Renal Cell,
pubmed-meshheading:2988459-Carcinoma, Small Cell,
pubmed-meshheading:2988459-Drug Evaluation,
pubmed-meshheading:2988459-Female,
pubmed-meshheading:2988459-Humans,
pubmed-meshheading:2988459-Interferon-gamma,
pubmed-meshheading:2988459-Kidney Neoplasms,
pubmed-meshheading:2988459-Lung Neoplasms,
pubmed-meshheading:2988459-Male,
pubmed-meshheading:2988459-Middle Aged,
pubmed-meshheading:2988459-Ovarian Neoplasms
|
pubmed:year |
1985
|
pubmed:articleTitle |
[Phase I-II study of recombinant interferon gamma].
|
pubmed:publicationType |
Journal Article,
English Abstract
|